Cargando…
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
Autores principales: | Aroldi, Andrea, Chiarle, Roberto, Gambacorti-Passerini, Carlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mayo Foundation for Medical Education and Research
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833532/ https://www.ncbi.nlm.nih.gov/pubmed/33673929 http://dx.doi.org/10.1016/j.mayocp.2020.12.030 |
Ejemplares similares
-
In Reply — Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
por: Temesgen, Zelalem, et al.
Publicado: (2021) -
Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019
por: Melody, Megan, et al.
Publicado: (2020) -
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas
por: Rindone, Giovanni, et al.
Publicado: (2022) -
Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2021) -
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
por: Inzoli, Elena, et al.
Publicado: (2022)